Healthcare

Request for TOC Request for Sample
BUY NOW

North America Human Leukocyte Antigen (HLA) Typing for Transplant Market – Industry Trends and Forecast to 2028

Healthcare | Published Report | Nov 2021 | North America | 350 Pages | No of Tables: 70 | No of Figures: 81

Report Description

North America Human Leukocyte Antigen (HLA) Typing for Transplant Market, By Products and Services (Reagents and Consumables, Instruments, Software and Services), Technology (Sequencing- Based Molecular Assays, Molecular Assay Technologies, Non- Molecular Assay Technologies), Transplant Type (Solid Organ Transplant, Haematopoietic Stem Cell Transplant), Application (Diagnostic Applications, Research Application), End User (Independent Reference Laboratories, Hospitals and Transplant Centres, Research Laboratories and Academic Institutes), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2028

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: North America Human Leukocyte Antigen (HLA) Typing for Transplant Market

North America human leukocyte antigen (HLA) typing for transplant market is expected to gain significant growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the North America human leukocyte antigen (HLA) typing for transplant market is growing with a CAGR of 8.0% in the forecast period of 2021 to 2028 and is expected to reach USD 634.68 million by 2028 from USD 357.61 million in 2020. Rising demand for organ transplant procedures is acting as driver for the growth of global human leukocyte typing for transplant market.

Human leukocyte antigen (HLA) typing is used to match patients and donors for bone marrow or cord blood transplants. HLA are proteins -- or markers -- found on most cells in the body. The immune system uses these markers to recognize which cells belong to the body and which do not.

Research has found that a donor must match a minimum of 6 HLA markers. Several Many times a closer match is required. A best match is found through detailed testing. As some HLA types are more common than others, some patients may face a greater challenge in finding a matching donor. Some HLA types are found more often in certain racial and ethnic groups.

A close match between a donor’s and a patient’s HLA markers is essential for a successful transplant outcome. HLA matching promotes the growth and development of new healthy blood cells (called engraftment) and reduces the risk of a post-transplant complication called graft-versus-host (GVHD) disease.

The high demand of organ donation, increasing innovations and technologies and novel product launch are also propelling the growth of the North America human leukocyte antigen (HLA) typing for transplant market.

A growing number of people are affected with by the HLA disorders which demand highly effective and advanced treatment to minimize the risk during the treatment. The healthcare systems need highly advanced drugs for numerous different types of HLA disorders during the treatment of patients. Therefore, the major market players are highly focusing on product launches and product approvals. Additionally, the government and regulatory bodies are supporting market players by virtue of product approval.

Rising product launches is acting as an opportunity for this market and is expected to impel the market growth for boosting the demand of global human leukocyte typing for transplant market.

Research on the human leukocyte antigen (HLA), is an extensively studied molecule involved in immunity and NGS technologies have revolutionised HLA typing procedure by providing fast and cost-effective technology. It is expected that lack skilled professionals is the major key challenge for the future growth of global human leukocyte antigen (HLA) typing for transplant market.

North America human leukocyte antigen (HLA) typing for transplant market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.  

Get Exclusive Sample Copy of this Report Here

North America Human Leukocyte Antigen (HLA) Typing for Transplant Market and Market Size

North America human leukocyte antigen (HLA) typing for transplant market is segmented on the basis of products and services, technology, transplant type, application, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of by products and services, North America human leukocyte antigen (HLA) typing for transplant market is segmented in reagents and consumables, instruments, software and services. In 2021, instruments segment is expected to dominate the market due to rising product launches by the key market players.
  • On the basis of technology, North America human leukocyte antigen (HLA) typing for transplant market is molecular assay technologies and non- molecular assay technologies.  In 2021, molecular assay technologies segment is expected to dominate the market because of the rising success and greater improvement in post-transplant outcome.
  • On the basis of transplant type, North America human leukocyte antigen (HLA) typing for transplant market is segmented solid organ transplant and haematopoietic stem cell transplant. In 2021, solid organ transplant segment is expected to dominate the market because it is most effective mode administration with better patient compliance.
  • On the basis of application, the North America human leukocyte antigen (HLA) typing for transplant market is segmented into diagnostic applications and research application. In 2021, diagnostic applications segment is expected to dominate the market because the increased incidence of vital organ failure, doctors tend to detect problem prior via diagnostic applications.
  • On the basis of end user, the North America human leukocyte antigen (HLA) typing for transplant market is segmented into independent reference laboratories, hospitals and transplant centres, research laboratories and academic institutes. In 2021, hospitals & transplant centers segment is expected to dominate the market owing to the high product launches in the market.

North America Human Leukocyte Antigen (HLA) Typing for Transplant Market Country Level Analysis

The North America human leukocyte antigen (HLA) typing for transplant market is analyzed and market size information is provided based on country, products and services, technology, transplant type, application, and end user.

Countries covered in the North America human leukocyte antigen (HLA) typing for transplant market report are U.S., Canada and Mexico.

U.S. is expected to dominate the North America human leukocyte antigen (HLA) typing for transplant market due to increasing government funding in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.   

Rising Healthcare Expenditure and Escalation in Innovations and Technologies in the North America Human Leukocyte Antigen (HLA) Typing for Transplant Market are Creating New Opportunities for Players in the North America Human Leukocyte Antigen (HLA) Typing for Transplant Market

North America human leukocyte antigen (HLA) typing for transplant market also provides you with detailed market analysis for every country growth in particular industry with the North America human leukocyte antigen (HLA) typing for transplant market sales, impact of advancement in the North America human leukocyte antigen (HLA) typing for transplant market and changes in regulatory scenarios with their support for the North America human leukocyte antigen (HLA) typing for transplant market in the period of 2011-2019.

Competitive Landscape and North America Human Leukocyte Antigen (HLA) Typing for Transplant Market Share Analysis

North America human leukocyte antigen (HLA) typing for transplant market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to North America human leukocyte antigen (HLA) typing for transplant market.

Major players covered in the report are Thermo Fisher Scientific Inc., Illumina, Inc., Luminex Corporation, QIAGEN, CareDX, Inc., Immucor Inc., Bio Rad Labaratories, Inc., Takara Bio Inc., BD, Fujirebio, TBG Diagnostics Limited, and GenDx.

DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies worldwide, which are further accelerating the North America human leukocyte antigen (HLA) typing for transplant market.

For instance,

  • In October 2017, TBG's HLAssure SE SBT Kits received the China CFDA approval for clinical use. This is the first approval for a High Resolution HLA Typing Kit in China. This helped the company to strengthened its footprint in China and boosted market growth


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT & SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 AVERAGE PRICE/TEST FOR HLA TYPING BY NEXT GENERATION SEQUENCING (USD)

4.2 PESTEL'S MODEL

4.3 PORTER'S 5 FORCES

5 REGIONAL SUMMARY

5.1 NORTH AMERICA

5.1.1 OVERVIEW

6 REGULATORY GUIDELINES FOR NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) FOR TRANSPLANT MARKET

6.1 U.S.

6.2 EUROPE

6.3 JAPAN

6.4 INDIA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING DEMAND FOR ORGAN TRANSPLANT PROCEDURES

7.1.2 GROWING TECHNOLOGICAL ADVANCEMENT & INNOVATIONS IN HLA TYPING

7.1.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES IN HLA TYPING

7.1.4 INCREASING CERTAIN DISEASES SUCH AS BLOOD CANCERS, AND GENETIC BLOOD DISORDERS

7.2 RESTRAINTS

7.2.1 HIGH COST OF HLA TYPING FOR TRANSPLANTATION PROCEDURE

7.2.2 LIMITED REIMBURSEMENTS POLICIES FOR ORGAN TRANSPLANT

7.3 OPPORTUNITIES

7.3.1 PRODUCT LAUNCHES, AND AGREEMENT BY MAJOR PLAYERS

7.3.2 RISING GOVERNMENT FUNDING FOR ORGAN DONATIONS

7.3.3 RISING PUBLIC AWARENESS FOR ORGAN TRANSPLANTATION

7.4 CHALLENGES

7.4.1 LESS NUMBER OF DONORS FOR ORGAN DONATION

7.4.2 DEARTH OF SKILLED PROFESSIONALS

8 COVID-19 IMPACT ON HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC DECISIONS FOR MANUFACTURERS

8.5 CONCLUSION

9 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES

9.1 OVERVIEW

9.2 INSTRUMENTS

9.3 REAGENTS AND CONSUMABLES

9.4 SOFTWARE & SERVICES

10 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY

10.1 OVERVIEW

10.2 MOLECULAR ASSAY TECHNOLOGIES

10.2.1 SEQUENCING-BASED MOLECULAR ASSAYS

10.2.1.1 NEXT-GENERATION SEQUENCING

10.2.1.2 SANGER SEQUENCING

10.2.1.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS

10.2.2 PCR-BASED MOLECULAR ASSAYS

10.2.2.1 SEQUENCE-SPECIFIC PRIMER-PCR

10.2.2.2 REAL-TIME PCR

10.2.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR

10.2.2.4 OTHER PCR-BASED MOLECULAR ASSAYS

10.3 NON-MOLECULAR ASSAY TECHNOLOGIES

11 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE

11.1 OVERVIEW

11.2 SOLID ORGAN TRANSPLANT

11.2.1 KIDNEY

11.2.2 LIVER

11.2.3 HEART

11.2.4 LUNG

11.2.5 PANCREAS

11.2.6 OTHERS

11.3 HEMATOPOIETIC STEM CELL TRANSPLANT

11.3.1 STEM CELL TRANSPLANT

11.3.2 BONE MARROW TRANSPLANT

12 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 DIAGNOSTIC APPLICATIONS

12.2.1 ANTIBODY SCREENING

12.2.2 CHIMERISM MONITORING

12.2.3 OTHERS

12.3 RESEARCH APPLICATIONS

13 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS & TRANSPLANT CENTERS

13.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES

13.4 INDEPENDENT REFERENCE LABORATORIES

14 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION

14.1 NORTH AMERICA

14.1.1 U.S.

14.1.2 CANADA

14.1.3 MEXICO

15 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

16 MARKET SHARE ANALYSIS: BY TECHNOLOGY

16.1 SEQUENCING BASED MOLECULAR ASSAYS

16.1.1 NORTH AMERICA

16.1.2 EUROPE

16.1.3 ASIA-PACIFIC

16.1.4 SOUTH AMERICA

16.1.5 MIDDLE EAST AND AFRICA

16.2 NGS SEQUENCING

16.2.1 NORTH AMERICA

16.2.2 EUROPE

16.2.3 ASIA-PACIFIC

16.2.4 SOUTH AMERICA

16.2.5 MIDDLE EAST AND AFRICA

16.3 SANGER SEQUENCING

16.3.1 NORTH AMERICA

16.3.2 EUROPE

16.3.3 ASIA-PACIFIC

16.3.4 SOUTH AMERICA

16.3.5 MIDDLE EAST AND AFRICA

16.4 PCR BASED MOLECULAR ASSAYS

16.4.1 NORTH AMERICA

16.4.2 EUROPE

16.4.3 ASIA-PACIFIC

16.4.4 SOUTH AMERICA

16.4.5 MIDDLE EAST AND AFRICA

16.5 REAL TIME PCR

16.5.1 NORTH AMERICA

16.5.2 EUROPE

16.5.3 ASIA-PACIFIC

16.5.4 SOUTH AMERICA

16.5.5 MIDDLE EAST AND AFRICA

16.6 SEQUENCE-SPECIFIC PRIMER-PCR

16.6.1 NORTH AMERICA

16.6.2 EUROPE

16.6.3 ASIA-PACIFIC

16.6.4 SOUTH AMERICA

16.6.5 MIDDLE EAST AND AFRICA

16.7 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR

16.7.1 NORTH AMERICA

16.7.2 EUROPE

16.7.3 ASIA-PACIFIC

16.7.4 SOUTH AMERICA

16.7.5 MIDDLE EAST AND AFRICA

17 COMPANY PROFILE

17.1 THERMO FISHER SCIENTIFIC INC.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENTS

17.1.6 SWOT ANALYSIS

17.2 ILLUMINA, INC.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.2.6 SWOT ANALYSIS

17.3 BIO-RAD LABORATORIES, INC.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.3.6 SWOT ANALYSIS

17.4 QIAGEN

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENTS

17.4.5.1 ACQUISITION

17.4.6 SWOT ANALYSIS

17.5 ROCHE SEQUENCING (A SUBSIDIARY OF F.HOFFMAN LA-ROCHE LTD.)

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENTS

17.5.6 SWOT ANALYSIS

17.6 BD

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENTS

17.7 BIOFORTUNA LIMITED

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENT

17.8 CARE DX, INC.

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENTS

17.9 CREATIVE BIOLABS

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.9.3.1 PRODUCT LAUNCH/UPDATE/APPROVAL

17.1 FUJIREBIO

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.10.4.1 CE CERTIFICATION

17.11 GENDX

17.11.1 COMPANY SNAPSHOT

17.11.2 PRODUCT PORTFOLIO

17.11.3 RECENT DEVELOPMENTS

17.12 IMMUCOR, INC.

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENT

17.12.3.1 PROUCT LAUNCH

17.13 LUMINEX CORPORATION

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENTS

17.14 OMIXON INC.

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.14.3.1 PRODUCT LAUNCH

17.15 TAKARA BIO INC

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENTS

17.15.4.1 LICENSING

17.15.5 PRODUCT LAUNCH

17.16 TBG DIAGNOSTICS LIMITED

17.16.1 COMPANY SNAPSHOT

17.16.2 REVENUE ANALYSIS

17.16.3 PRODUCT PORTFOLIO

17.16.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

List of Table

TABLE 1 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AVERAGE PRICE/TEST FOR HLA TYPING BY NEXT GENERATION SEQUENCING

TABLE 2 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BYPRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 3 NORTH AMERICA INSTRUMENTS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA REAGENTS AND CONSUMABLES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA SOFTWARE & SERVICES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY , 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY , 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA NON-MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE , 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, REGION, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA RESEARCH APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA HOSPITALS & TRANSPLANT CENTERS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA RESEARCH LABORATORIES & ACADEMIC INSTITUTES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA OTHERS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 38 U.S. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 39 U.S. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 40 U.S. MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 41 U.S. SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 42 U.S. PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 43 U.S. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 44 U.S. SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 45 U.S. HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 46 U.S. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 47 U.S. DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 48 U.S. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 49 CANADA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 50 CANADA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 51 CANADA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 52 CANADA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 53 CANADA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 54 CANADA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 55 CANADA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 56 CANADA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 57 CANADA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 58 CANADA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 59 CANADA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 60 MEXICO HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 61 MEXICO HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 62 MEXICO MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 63 MEXICO SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 64 MEXICO PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 65 MEXICO HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 66 MEXICO SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 67 MEXICO HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)

TABLE 68 MEXICO HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 69 MEXICO DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 70 MEXICO HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET:

FIGURE 3 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION

FIGURE 11 INCREASING DEMAND FOR ORGAN TRANSPLANTATION, AND RISING R&D ACTIVITIES IN HLA TYPING ARE EXPECTED TO DRIVE THE NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN 2021 & 2028

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET

FIGURE 15 IN 2021, ESTIMATED NEW CASES OF LEUKEMIA, MYELOMA, AND LYMPHOMA IN THE U.S.

FIGURE 16 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2020

FIGURE 17 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2021-2028 (USD MILLION)

FIGURE 18 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, CAGR (2021-2028)

FIGURE 19 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE

FIGURE 20 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2020

FIGURE 21 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)

FIGURE 22 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, CAGR (2021-2028)

FIGURE 23 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 24 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2020

FIGURE 25 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2021-2028 (USD MILLION)

FIGURE 26 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, CAGR (2021-2028)

FIGURE 27 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2020

FIGURE 29 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 30 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 31 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 32 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, 2021-2028 (USD MILLION)

FIGURE 33 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 34 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: END USERS, CAGR (2021-2028)

FIGURE 35 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, LIFELINE CURVE

FIGURE 36 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SNAPSHOT (2020)

FIGURE 37 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY REGION (2020)

FIGURE 38 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY REGION (2021 & 2028)

FIGURE 39 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY REGION (2020 & 2028)

FIGURE 40 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCT & SERVICES (2021-2028)

FIGURE 41 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SNAPSHOT (2020)

FIGURE 42 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020)

FIGURE 43 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 44 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 45 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCT & SERVICES (2021-2028)

FIGURE 46 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY SHARE 2020 (%)

FIGURE 47 NORTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 48 EUROPE SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 49 ASIA-PACIFIC SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 50 SOUTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 51 MIDDLE EAST AND AFRICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 52 NORTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 53 EUROPE NGS SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 54 ASIA-PACIFIC NGS SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 55 SOUTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 56 MIDDLE EAST AND AFRICA NGS SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 57 NORTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 58 EUROPE SANGER SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 59 ASIA-PACIFIC SANGER SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 60 SOUTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 61 MIDDLE EAST AND AFRICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 62 NORTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 63 EUROPE PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 64 ASIA-PACIFIC PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 65 SOUTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 66 MIDDLE EAST AND AFRICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 67 NORTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)

FIGURE 68 EUROPE REAL TIME PCR: COMPANY SHARE 2020 (%)

FIGURE 69 ASIA-PACIFIC REAL TIME PCR: COMPANY SHARE 2020 (%)

FIGURE 70 SOUTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)

FIGURE 71 MIDDLE EAST AND AFRICA REAL TIME PCR: COMPANY SHARE 2020 (%)

FIGURE 72 NORTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)

FIGURE 73 EUROPE SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)

FIGURE 74 ASIA-PACIFIC SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)

FIGURE 75 SOUTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)

FIGURE 76 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)

FIGURE 77 NORTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)

FIGURE 78 EUROPE SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)

FIGURE 79 ASIA-PACIFIC SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)

FIGURE 80 SOUTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)

FIGURE 81 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)

View Infographics

FIGURE 1 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET:

FIGURE 3 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION

FIGURE 11 INCREASING DEMAND FOR ORGAN TRANSPLANTATION, AND RISING R&D ACTIVITIES IN HLA TYPING ARE EXPECTED TO DRIVE THE NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN 2021 & 2028

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET

FIGURE 15 IN 2021, ESTIMATED NEW CASES OF LEUKEMIA, MYELOMA, AND LYMPHOMA IN THE U.S.

FIGURE 16 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2020

FIGURE 17 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2021-2028 (USD MILLION)

FIGURE 18 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, CAGR (2021-2028)

FIGURE 19 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE

FIGURE 20 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2020

FIGURE 21 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)

FIGURE 22 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, CAGR (2021-2028)

FIGURE 23 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 24 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2020

FIGURE 25 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2021-2028 (USD MILLION)

FIGURE 26 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, CAGR (2021-2028)

FIGURE 27 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2020

FIGURE 29 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 30 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 31 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 32 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, 2021-2028 (USD MILLION)

FIGURE 33 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 34 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: END USERS, CAGR (2021-2028)

FIGURE 35 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, LIFELINE CURVE

FIGURE 36 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SNAPSHOT (2020)

FIGURE 37 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY REGION (2020)

FIGURE 38 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY REGION (2021 & 2028)

FIGURE 39 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY REGION (2020 & 2028)

FIGURE 40 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCT & SERVICES (2021-2028)

FIGURE 41 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SNAPSHOT (2020)

FIGURE 42 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020)

FIGURE 43 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 44 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 45 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCT & SERVICES (2021-2028)

FIGURE 46 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY SHARE 2020 (%)

FIGURE 47 NORTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 48 EUROPE SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 49 ASIA-PACIFIC SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 50 SOUTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 51 MIDDLE EAST AND AFRICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 52 NORTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 53 EUROPE NGS SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 54 ASIA-PACIFIC NGS SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 55 SOUTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 56 MIDDLE EAST AND AFRICA NGS SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 57 NORTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 58 EUROPE SANGER SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 59 ASIA-PACIFIC SANGER SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 60 SOUTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 61 MIDDLE EAST AND AFRICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)

FIGURE 62 NORTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 63 EUROPE PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 64 ASIA-PACIFIC PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 65 SOUTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 66 MIDDLE EAST AND AFRICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)

FIGURE 67 NORTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)

FIGURE 68 EUROPE REAL TIME PCR: COMPANY SHARE 2020 (%)

FIGURE 69 ASIA-PACIFIC REAL TIME PCR: COMPANY SHARE 2020 (%)

FIGURE 70 SOUTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)

FIGURE 71 MIDDLE EAST AND AFRICA REAL TIME PCR: COMPANY SHARE 2020 (%)

FIGURE 72 NORTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)

FIGURE 73 EUROPE SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)

FIGURE 74 ASIA-PACIFIC SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)

FIGURE 75 SOUTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)

FIGURE 76 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)

FIGURE 77 NORTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)

FIGURE 78 EUROPE SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)

FIGURE 79 ASIA-PACIFIC SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)

FIGURE 80 SOUTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)

FIGURE 81 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19